Biodistribution of Adeno-Associated Virus Serotype 5 Viral Vectors Following Intrathecal Injection.

The pharmacokinetic profile of AAV particles following intrathecal delivery has not yet been clearly defined. The present study evaluated the distribution profile of adeno-associated virus serotype 5 (AAV5) viral vectors following lumbar intrathecal injection in mice. After a single bolus intrathecal injection, viral DNA concentrations in mouse whole blood, spinal cord, and peripheral tissues were determined using quantitative polymerase chain reaction (qPCR). The kinetics of AAV5 vector in whole blood and the concentration over time in spinal and peripheral tissues were analyzed. Distribution of the AAV5 vector to all levels of the spinal cord, dorsal root ganglia, and into systemic circulation occurred rapidly within 30 min following injection. Vector concentration in whole blood reached a maximum 6 h postinjection with a half-life of approximately 12 h. Area under the curve data revealed the highest concentration of vector distributed to dorsal root ganglia tissue. Immunohistochemical analysis revealed AAV5 particle colocalization with the pia mater at the spinal cord and macrophages in the dorsal root ganglia (DRG) 30 min after injection. These results demonstrate the widespread distribution of AAV5 particles through cerebrospinal fluid and preferential targeting of DRG tissue with possible clearance mechanisms via DRG macrophages.

[1]  J. Rasko,et al.  Journey to the Center of the Cell: Tracing the Path of AAV Transduction. , 2020, Trends in molecular medicine.

[2]  R. Tubbs,et al.  Our current understanding of the lymphatics of the brain and spinal cord , 2018, Clinical anatomy.

[3]  P. Allen,et al.  Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates , 2018, Molecular therapy. Methods & clinical development.

[4]  B. Ravina,et al.  Gene therapy for neurological disorders: progress and prospects , 2018, Nature Reviews Drug Discovery.

[5]  K. Barszcz,et al.  Lymphatic drainage of cerebrospinal fluid in mammals – are arachnoid granulations the main route of cerebrospinal fluid outflow? , 2018, Biologia.

[6]  N. Boulis,et al.  AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials , 2018, Expert opinion on biological therapy.

[7]  D. Janigro,et al.  The role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system? , 2018, Acta Neuropathologica.

[8]  M. Detmar,et al.  Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice , 2017, Nature Communications.

[9]  F. Jamme,et al.  Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease , 2017, Acta neuropathologica communications.

[10]  W. Strohl,et al.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy , 2017, BioDrugs.

[11]  C. Ciron,et al.  Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders , 2017, Gene Therapy.

[12]  Arun Srivastava,et al.  In vivo tissue-tropism of adeno-associated viral vectors. , 2016, Current opinion in virology.

[13]  P. Dubový,et al.  Direct communication of the spinal subarachnoid space with the rat dorsal root ganglia. , 2016, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[14]  W. Pardridge,et al.  CSF, blood-brain barrier, and brain drug delivery , 2016, Expert opinion on drug delivery.

[15]  R. Thorpe,et al.  Systematic Comparison and Validation of Quantitative Real-Time PCR Methods for the Quantitation of Adeno-Associated Viral Products , 2015, Human gene therapy methods.

[16]  Y. Tao,et al.  Current gene therapy using viral vectors for chronic pain , 2015, Molecular pain.

[17]  L. Belur,et al.  Supraspinal gene transfer by intrathecal adeno-associated virus serotype 5 , 2014, Front. Neuroanat..

[18]  X. Navarro,et al.  Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy , 2014, Molecular therapy. Methods & clinical development.

[19]  S. Rumpel,et al.  Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain , 2013, PloS one.

[20]  K. Gannon,et al.  Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. , 2013, Molecular Pharmaceutics.

[21]  G. Gao,et al.  Gene Transfer in the Liver Using Recombinant Adeno‐Associated Virus , 2013, Current protocols in microbiology.

[22]  R. Samulski,et al.  Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.

[23]  R. Samulski,et al.  Viral vectors for gene delivery to the central nervous system , 2012, Neurobiology of Disease.

[24]  M. Papisov,et al.  Delivery of proteins to CNS as seen and measured by positron emission tomography , 2012, Drug Delivery and Translational Research.

[25]  Gabriele Mittermeyer,et al.  Axonal transport of adeno-associated viral vectors is serotype-dependent , 2012, Gene Therapy.

[26]  M. Nonnenmacher,et al.  Intracellular transport of recombinant adeno-associated virus vectors , 2012, Gene Therapy.

[27]  R. Herzog.  Hepatic AAV gene transfer and the immune system: friends or foes? , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  L. Belur,et al.  Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. , 2010, Molecular pain.

[29]  A. Beutler.  AAV provides an alternative for gene therapy of the peripheral sensory nervous system. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  E. Ehlert,et al.  Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Marina Vardanyan,et al.  Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: Implications for chemical-induced peripheral sensory neuropathies , 2008, Molecular pain.

[33]  H. Stockman,et al.  Effect of anatomical fine structure on the dispersion of solutes in the spinal subarachnoid space. , 2007, Journal of biomechanical engineering.

[34]  Tania Nolan,et al.  Quantification of mRNA using real-time RT-PCR , 2006, Nature Protocols.

[35]  S. Abram,et al.  Permeability of Injured and Intact Peripheral Nerves and Dorsal Root Ganglia , 2006, Anesthesiology.

[36]  G. Hocking,et al.  Intrathecal drug spread. , 2004, British journal of anaesthesia.

[37]  U Klose,et al.  The Influence of Pulse and Respiration on Spinal Cerebrospinal Fluid Pulsation , 2004, Investigative radiology.

[38]  Y. Imai,et al.  Iba1-expressing microglia respond to herpes simplex virus infection in the mouse trigeminal ganglion. , 2003, Brain research. Molecular brain research.

[39]  W. Low,et al.  In vivo transduction of cerebellar Purkinje cells using adeno-associated virus vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  Y. Imai,et al.  Upregulated Expression of Iba1 Molecules in the Central Nervous System of Mice in Response to Neurovirulent Influenza A Virus Infection , 2000, Microbiology and immunology.

[41]  S. Shafer,et al.  Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Intrathecal Neostigmine Methylsulfate in Humans , 1998, Anesthesiology.

[42]  M. Miura,et al.  Lymphatic drainage of the cerebrospinal fluid from monkey spinal meninges with special reference to the distribution of the epidural lymphatics. , 1998, Archives of histology and cytology.

[43]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.

[44]  J. Brierley.  THE PENETRATION OF PARTICULATE MATTER FROM THE CEREBROSPINAL FLUID INTO THE SPINAL GANGLIA, PERIPHERAL NERVES, AND PERIVASCULAR SPACES OF THE CENTRAL NERVOUS SYSTEM , 1950, Journal of neurology, neurosurgery, and psychiatry.

[45]  G. Wilcox,et al.  Detailed Method for Intrathecal Delivery of Gene Therapeutics by Direct Lumbar Puncture in Mice. , 2019, Methods in molecular biology.

[46]  C. Vite,et al.  Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. , 2018, Human gene therapy.

[47]  G. Gao,et al.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders. , 2016, Methods in molecular biology.

[48]  Michael Detmar,et al.  A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules , 2015 .

[49]  P. Pivirotto,et al.  AAV9-mediated Expression of a Non-self Protein in Nonhuman Primate Central Nervous System Triggers Widespread Neuroinflammation Driven by Antigen-presenting Cell Transduction. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  M. Sands.  AAV-mediated liver-directed gene therapy. , 2011, Methods in molecular biology.